These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18176993)

  • 1. Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis.
    Pinto JA; Rego I; Rodríguez-Gomez M; Cañete JD; Fernandez-López C; Freire M; Fernandez-Sueiro JL; Sanmarti R; Blanco FJ
    J Rheumatol; 2008 Jan; 35(1):177-8. PubMed ID: 18176993
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
    Criswell LA; Lum RF; Turner KN; Woehl B; Zhu Y; Wang J; Tiwari HK; Edberg JC; Kimberly RP; Moreland LW; Seldin MF; Bridges SL
    Arthritis Rheum; 2004 Sep; 50(9):2750-6. PubMed ID: 15457442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.
    Cuchacovich M; Ferreira L; Aliste M; Soto L; Cuenca J; Cruzat A; Gatica H; Schiattino I; Pérez C; Aguirre A; Salazar-Onfray F; Aguillón JC
    Scand J Rheumatol; 2004; 33(4):228-32. PubMed ID: 15370717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients.
    Martinez A; Salido M; Bonilla G; Pascual-Salcedo D; Fernandez-Arquero M; de Miguel S; Balsa A; de la Concha EG; Fernandez-Gutierrez B
    Arthritis Rheum; 2004 Apr; 50(4):1077-82. PubMed ID: 15077289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.
    Miceli-Richard C; Comets E; Verstuyft C; Tamouza R; Loiseau P; Ravaud P; Kupper H; Becquemont L; Charron D; Mariette X
    Ann Rheum Dis; 2008 Apr; 67(4):478-84. PubMed ID: 17673491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density in patients with rheumatoid arthritis treated with infliximab.
    Vis M; Voskuyl AE; Wolbink GJ; Dijkmans BA; Lems WF;
    Ann Rheum Dis; 2005 Feb; 64(2):336-7. PubMed ID: 15647447
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor necrosis factor alpha haplotypes versus tumor necrosis factor alpha -308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis.
    Mugnier B; Roudier J
    Arthritis Rheum; 2004 Dec; 50(12):4075-6; author reply 4076-7. PubMed ID: 15593229
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
    Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
    Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism.
    Chatzikyriakidou A; Georgiou I; Voulgari PV; Venetsanopoulou AI; Drosos AA
    Rheumatology (Oxford); 2007 Jun; 46(6):1034-5. PubMed ID: 17409133
    [No Abstract]   [Full Text] [Related]  

  • 11. Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis.
    Rojas-Villarraga A; Diaz FJ; Calvo-Páramo E; Salazar JC; Iglesias-Gamarra A; Mantilla RD; Anaya JM
    J Autoimmun; 2009 Feb; 32(1):64-9. PubMed ID: 19117726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics.
    Fonseca JE; Carvalho T; Cruz M; Nero P; Sobral M; Mourão AF; Cavaleiro J; Ligeiro D; Abreu I; Carmo-Fonseca M; Branco JC
    Ann Rheum Dis; 2005 May; 64(5):793-4. PubMed ID: 15834068
    [No Abstract]   [Full Text] [Related]  

  • 13. Infliximab improves vascular stiffness in patients with rheumatoid arthritis.
    Wong M; Oakley SP; Young L; Jiang BY; Wierzbicki A; Panayi G; Chowienczyk P; Kirkham B
    Ann Rheum Dis; 2009 Aug; 68(8):1277-84. PubMed ID: 18930987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells.
    Tanino M; Matoba R; Nakamura S; Kameda H; Amano K; Okayama T; Nagasawa H; Suzuki K; Matsubara K; Takeuchi T
    Biochem Biophys Res Commun; 2009 Sep; 387(2):261-5. PubMed ID: 19577537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic association of the major histocompatibility complex with rheumatoid arthritis implicates two non-DRB1 loci.
    Vignal C; Bansal AT; Balding DJ; Binks MH; Dickson MC; Montgomery DS; Wilson AG
    Arthritis Rheum; 2009 Jan; 60(1):53-62. PubMed ID: 19116923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
    Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
    Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
    [No Abstract]   [Full Text] [Related]  

  • 18. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
    de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
    Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic epidemiology of rheumatoid arthritis.
    Oliver JE; Worthington J; Silman AJ
    Curr Opin Rheumatol; 2006 Mar; 18(2):141-6. PubMed ID: 16462519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.